ReviewCancers2021
Hodgkin Lymphoma in People Living with HIV.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network.JNCI cancer spectrum · 2026Article
- Sex differences in cancer incidence among people with HIV infection in the United States.Journal of the National Cancer Institute · 2026Article
- Integrating Flow Cytometry in the Diagnostic Work of HIV-Associated Hodgkin's Lymphomas.Journal of cellular and molecular medicine · 2026Review
- Review
- Research trends between acquired immune deficiency syndrome and hematological malignancies: a bibliometric analysis.Discover oncology · 2025Article
- Current State of AIDS-Related Malignant Lymphoma.Viruses · 2025Review
- Review
- Managing HIV-Associated Hodgkin Lymphoma During the COVID-19 Pandemic: Case Report and Literature Review.Viruses · 2025Review
- Article
- Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China.Frontiers in immunology · 2025Article
- A landscape review with novel criteria to evaluate microbial drivers for cancer: priorities for innovative research targeting excessive cancer mortality in sub-Saharan Africa.Frontiers in cellular and infection microbiology · 2025Review
- HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma.Blood advances · 2024Article
- Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020.Scientific reports · 2024Article
- Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.HemaSphere · 2024Article
- Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study.HemaSphere · 2024Article
- When Lymphoma Strikes the Pancreas: A Rare Presentation of Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in a Human Immunodeficiency Virus-Positive Patient.Journal of hematology · 2023Article
- Hodgkin Lymphoma-The Spectrum from Diagnostics to Molecular Science, Movement and Current Treatment Approaches.Cancers · 2023Article
- CD4Open life sciences · 2023Article
- Primary Bone Marrow HIV-Associated Hodgkin Lymphoma Complicated by Hemophagocytic Lymphohistiocytosis.Genes · 2022Article
- A Rare Case of Good Outcome of Hodgkin Lymphoma in a Patient with HIV on Antiretroviral Therapy (ART).The American journal of case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Despite widespread use of combined antiretroviral therapy (cART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally treated with cART. While the incidence of aggressive forms of non-Hodgkin lymphoma decreased after the advent of cART, incidence of Hodgkin lymphoma (HL) has increased among PLWH in recent decades. The coinfection of Epstein-Barr virus plays a crucial role in the pathogenesis of HL in the HIV setting. Currently, PLWH with HRL, including HL, are treated similarly to HIV-negative patients and, importantly, the prognosis of HL in PLWH is approaching that of the general population. In this regard, effective cART during chemotherapy is strongly recommended since it has been shown to improve survival rates in all lymphoma subtypes, including HL. As a consequence, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential drug-drug interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PLWH with HL. In this article the authors review and update the epidemiological, clinical and biological aspects of HL presenting in PLWH with special emphasis on advances in prognosis and the factors that have contributed to it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.